Home
Scholarly Works
Final efficacy results of NCIC CTG IND.202: A...
Conference

Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM)

Authors

Petrella TM; Mihalcioiu CLD; McWhirter E; Belanger K; Savage KJ; Song X; Hamid O; Cheng T; Davis ML; Lee CW

Volume

31

Publisher

LIPPINCOTT WILLIAMS & WILKINS

Publication Date

May 20, 2013

Name of conference

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

Conference place

IL, Chicago

Conference start date

May 31, 2013

Conference end date

June 4, 2013

Conference proceedings

JOURNAL OF CLINICAL ONCOLOGY

Issue

15

ISSN

0732-183X

Labels

Fields of Research (FoR)

Contact the Experts team